Funds holding SCRIBE THERAPEUTICS INC
ISIN US8110331092 · United States
- Fund holders
- 2
- Of which ETFs
- 1 1 other fund
- Value held
- 9.5M $
- Share of capital
- 2.6 % of 18.9M shares on Aug 31, 2026
2 tracked funds declare this company. So these figures do not say who owns it.
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| ARK Genomic Revolution ETF ARK ETF Trust | 352,097 | 6.9M $ | 0.44 % | 1.86 % | as of Jul 31, 2026 ↗ |
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 135,567 | 2.6M $ | 0.23 % | 0.72 % | as of Jul 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| ARK Genomic Revolution ETF ARK ETF Trust | 0.44 % | as of Jul 31, 2026 ↗ |
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 0.23 % | as of Jul 31, 2026 ↗ |
Declared shareholders of SCRIBE THERAPEUTICS INC
There are 4 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Avoro Capital Advisors LLC and 2 others | 16.37 % | 3,088,888 | as of Jul 24, 2026 · SCHEDULE 13D |
| RA Capital Management, L.P. and 3 others | 9.60 % | 1,802,178 | as of Jul 27, 2026 · SCHEDULE 13G |
| ELI LILLY & Co | 7.30 % | 1,388,161 | as of Jul 23, 2026 · SCHEDULE 13D |
| ORBIMED ADVISORS LLC and 1 other | 7.20 % | 1,348,825 | as of Jul 27, 2026 · SCHEDULE 13D |
Cite this page
Titelia. "Funds holding SCRIBE THERAPEUTICS INC". https://titelia.com/en/stocks/scribe-therapeutics-inc-US8110331092